On May 7, 2019, the 2019 Guangdong-Hong Kong-Macao Economic, Technological and Trade Cooperation and Exchange Conference, hosted by the People's Government of Guangdong Province, the Government of the Hong Kong Special Administrative Region and the Government of the Macao Special Administrative Region, and hosted by the Department of Commerce of Guangdong Province, the Hong Kong Bureau of Commerce and Economic Development and the Macao Trade and Investment Promotion Bureau, was held at the Hong Kong Convention and Exhibition Center.

2019 Guangdong-Hong Kong-Macao Economic, Technological and Trade Cooperation Exchange Conference

GDIC was invited to attend the exchange meeting. Zhong Yubin, Chief Operating Officer of Guangmin Investment and Secretary-General of the Guangdong-Hong Kong-Macao Greater Bay Area Bio-pharmaceutical Industry Promotion Association, delivered a keynote speech entitled "Investment and Cooperation Opportunities in the Guangdong-Hong Kong-Macao Greater Bay Area Bio-pharmaceutical Industry" at the Bio-pharmaceutical and Smart Health Forum.

Zhong Yubin, Chief Operating Officer of Guangmin Investment, delivered a keynote speech

Zhong Yubin said that biomedicine has the characteristics of high risk, high investment, high technology and long cycle, which determine the requirements of its centralized development. The bio-pharmaceutical industry not only needs to get through the circulation mechanism of technology, capital, talent and other elements in the Greater Bay Area of Guangdong, Hong Kong and Macao, but also needs to vigorously introduce international advanced resources to form a good industrial ecology and develop rapidly.

Based on Guangdong, Hong Kong and Macao Greater Bay Area, based on the good industrial foundation of Guangzhou, and taking industrial investment as the main line, and in combination with high-quality scientific research, technology and human resources in the Tokyo Bay Area, Guangmin Investment is vigorously promoting the construction of Sino-Japanese biomedical industrial park, which will serve as the physical space of the first national-level biomedical industry between China and Japan, and the carrier of cooperation between China and Japan in the field of life science, promote the industrial agglomeration and development, and form an industrial ecosystem.